Physician profile
Tong Jing
NPI 1316916778
$11,009.85
in general payments reported to CMS, 2019-2025
21 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936 · 2020: $1,339 · 2021: $1,423 · 2022: $1,426 · 2023: $1,705 · 2024: $1,933 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,885.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,168.22 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $1,587.31 | 2019-2025 | |
| Abbvie INC. | $1,163.91 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $999.28 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $963.11 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $773.60 | 2020-2024 | Linzess |
| Pfizer INC. | $380.00 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.52 | 2019-2024 | Entyvio |
| Madrigal Pharmaceuticals | $236.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $236.70 | 2019-2020 | |
| Intra-Sana Laboratories | $198.57 | 2022-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Nestle Healthcare Nutrition INC. | $192.39 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $188.48 | 2019-2022 | |
| Redhill Biopharma INC. | $154.19 | 2020-2021 | |
| Celgene Corporation | $146.33 | 2023 | Zeposia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $116.94 | 2019 | |
| Concordia Pharmaceuticals INC. | $106.30 | 2019 | |
| Braintree Laboratories, INC. | $58.77 | 2019-2021 | |
| Evoke Pharma, INC. | $40.01 | 2020-2022 | |
| Janssen Biotech, INC. | $23.83 | 2025 | Tremfya |
| Celltrion USA INC. | $21.48 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tong Jing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.